Skip to main content
Premium Trial:

Request an Annual Quote

Dako Partners with Genentech on Companion Dx

NEW YORK (GenomeWeb News) – Danish diagnostics firm Dako today said that it has signed an agreement to provide companion diagnostics for Genentech's trastuzumab (Herceptin) for patients with advanced HER2-positive stomach cancer.

The deal calls for Genentech, which is a wholly-owned subsidiary of Roche, to collaborate with Dako on US regulatory submissions of the HercepTest and HER2 FISH pharmDx as companion diagnostics for Herceptin in treating these patients. The tests are already used to identify patients with HER2-positive metastatic breast cancer who are eligible for treatment with Herceptin.

Based on the results of a Phase III study, which was presented at the American Society for Clinical Oncology annual meeting in late May, Genentech said that it may file for US approval of Herceptin in treating advanced HER2-positive stomach cancer.

"We see great potential in a strong collaborative approach between biotechnology and pharmaceutical companies, and diagnostic companies, in targeting the right drugs for the right patients, both to improve patient care and more efficiently manage health care costs," Dako President and CEO Lars Holmkvist said in a statement.

Dako said that roughly 22 percent of stomach tumors are HER2-positive. It cited figures from the American Cancer Society that there are more than 1 million new cases of gastric or stomach cancer each year worldwide.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.